Efavirenz
3 NDCs across 3 manufacturers|3 Generic,0 Brand
Efavirenz is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Sep 17, 1998, and the first generic was approved Feb 17, 2016. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $4 million on Efavirenz across 11,000 claims for 1,545 beneficiaries.
Efavirenz is available as 3 NDCs from 3 manufacturers (3 generic, 0 brand), with NADAC prices from $1.28 to $1.28 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
3G / 0B
Manufacturers
3
competing in market
Price Spread
$1.28 – $1.28
per EA
7d Activity
avg -5.4% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Camber Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
3 manufacturers producing EFAVIRENZ
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
EFAVIRENZ 600 MG TABLET | $1.2758 per EA | -5.43% |
EFAVIRENZ 600 MG TABLET | $1.2758 per EA | -5.43% |
EFAVIRENZ 600 MG TABLET | $1.2758 per EA | -5.43% |
Frequently Asked Questions
What is Efavirenz used to treat?
Efavirenz is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
When did Efavirenz become available as a generic?
FDA approved the first generic Efavirenz (ANDA) on Feb 17, 2016. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Efavirenz?
In 2024, Medicare Part D spent $4 million on Efavirenz across 11,000 claims for 1,545 beneficiaries.
How many Efavirenz products are on the market?
The Efavirenz drug market contains 3 NDCs from 3 manufacturers — 3 generic and 0 brand products.
What is the price range for Efavirenz?
NADAC reference prices for Efavirenz range from $1.2758 to $1.2758 per EA.
Which manufacturers make Efavirenz?
3 manufacturers list Efavirenz in NADAC. Ranked by number of NDCs, the largest are Camber Pharmaceuticals Inc. (1), Aurobindo Pharma Limited (1), Cipla USA Inc. (1).
How has the price of Efavirenz changed recently?
Over the past 7 days, 0 Efavirenz NDCs rose and 3 fell, with a market-wide average change of -5.4%.